Latin America Cancer Targeted Therapy Market Report Outlook (2021–2031)

Evolving Approaches to Genomic Profiling and Biomarkers

Advancements in genomic profiling and biomarker discovery have become powerful market drivers. The widespread adoption of next‑generation sequencing (NGS), whole‑exome sequencing, and liquid biopsy technologies supports the precise identification of genetic alterations such as HER2, EGFR, ALK, and PIK3CA mutations. This molecular-level understanding has fostered precision medicine approaches where therapies are tailored to an individual patient's tumor profile, moving away from one‑size‑fits‑all chemotherapy regimens. Improved biomarker discovery enhances drug development efficiency, enables better patient stratification, and increases the likelihood of successful clinical outcomes.

Biomarker testing also facilitates real‑time disease monitoring and minimal residual disease tracking, broadening the clinical use of targeted therapies beyond initial treatment. As healthcare systems in Latin America gradually adopt reimbursement frameworks for genomic testing, clinicians increasingly rely on precision diagnostics to guide therapeutic decisions. Collectively, advancements in genomic profiling are expanding eligible patient populations, improving outcomes, and driving sustained growth in the targeted therapy market across the region.

Expanding Precision Therapies for Rare Genetic Cancers

Expansion of targeted therapies into rare cancers and genetically defined tumor subtypes presents a major market opportunity. Rare tumors historically suffered from limited treatment options due to small patient numbers and high development costs. However, genomic profiling has revealed actionable genetic drivers across multiple tumor types that can be addressed by targeted therapies.

Tumor‑agnostic treatment approaches—targeting biomarkers such as NTRK fusions, RET rearrangements, and BRAF mutations—enable therapies to be used based on genetic profiles rather than tumor origin, broadening their clinical applicability. These advances allow pharmaceutical companies to expand indications across rare malignancies, significantly increasing potential patient populations. Supportive regulatory frameworks and orphan drug incentives in some Latin American countries can improve commercial viability and accelerate access.

From a clinical perspective, targeted therapies often offer superior efficacy and tolerability compared to traditional chemotherapy in genetically defined cancers. Participation in multinational basket and umbrella trials also reduces development timelines and fosters inclusion of Latin American patient cohorts. As health systems strengthen molecular diagnostic adoption and real‑world evidence collection, expansion into rare, mutation-driven cancers represents a strategic growth avenue for targeted therapy uptake in Latin America.

The "Latin America Cancer Targeted Therapy Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• Latin America Cancer Targeted Therapy market size and forecast at regional and country levels for key segments covered under the scope
• Latin America Cancer Targeted Therapy market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Latin America Cancer Targeted Therapy market analysis covering key trends, regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Latin America Cancer Targeted Therapy market
• Detailed company profiles, including SWOT analysis

The geographical scope of the Latin America Cancer Targeted Therapy market report is divided into: Mexico, Brazil, Argentina, Peru, Chile, and Colombia. Brazil held the largest share in 2024.

Brazil dominates the Latin America cancer targeted therapy market due to its large population, advanced oncology infrastructure, and stronger pharmaceutical distribution networks. Brazil's private and public oncology centers have greater access to targeted therapies and precision diagnostic services compared to other regional markets. Mexico follows closely, supported by expanding healthcare expenditure, growing clinical research participation, and enhanced access to molecular testing across major urban centers. Mexico's oncology landscape reflects improved adoption of targeted regimens for breast, lung, and colorectal cancers. Argentina and Colombia show robust incremental growth as healthcare systems integrate targeted therapies into treatment guidelines and expand diagnostic capabilities. Smaller markets such as Chile and Peru are registering early gains in targeted therapy uptake as investments in cancer centers, clinician training, and reimbursement frameworks evolve. Across the region, hospitals and specialized cancer clinics are primary end users of targeted therapies due to centralized treatment protocols and the need for clinical administration. Retail pharmacies increasingly facilitate access to oral targeted agents, while online channels support broader patient reach.

• The report includes qualitative and quantitative data in the Latin America Cancer Targeted Therapy market across therapy type, indication, distribution channel, and geography.
• The report starts with the key takeaways (chapter 2), highlighting key trends and outlook of the Latin America Cancer Targeted Therapy market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the Latin America Cancer Targeted Therapy market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the Latin America Cancer Targeted Therapy market scenario, in terms of historical market revenues, and forecast till the year 2033.
• Chapters 7 to 11 cover Latin America Cancer Targeted Therapy market segments by therapy type, indication, distribution channel, and geography across Mexico, Brazil, Argentina, Peru, Chile, and Colombia. They cover the market revenue, forecast, and factors driving the market.
• Chapter 12 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 13 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 14 provides detailed profiles of the major companies operating in the Cancer Targeted Therapy market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 15, i.e., the appendix, is inclusive of a brief overview of the company, a list of abbreviations, and a disclaimer.

The Latin America Cancer Targeted Therapy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the Latin America cancer targeted therapy market are:

• In May 2025, Roche's Mexico oncology research unit advanced multicenter clinical trials focusing on HER2‑positive and triple‑negative breast cancer, integrating genomic profiling into precision treatment protocols across Latin American sites. This expansion highlights the company's commitment to regional oncology research and real‑world evidence generation.
• In March 2025, AstraZeneca unveiled plans to acquire EsoBiotec, a biotech developing in‑vivo cell therapy technologies for cancer. The deal—with an upfront payment of US$ 425 million and up to US$ 575 million in milestones—aims to transform cell therapy by genetically modifying immune cells inside the body, complementing the company's targeted oncology strategies.